Authors' Reply to Moura et al.: "Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk"

Drugs Aging. 2021 Jun;38(6):539-541. doi: 10.1007/s40266-021-00856-4. Epub 2021 Apr 19.

Authors

Suraj Rajasimhan¹, Omer Pamuk², James D Katz²

Affiliations

¹ Clinical Pharmacy Specialist-Pharmacotherapy, Pharmacy Department, National Institutes of Health Clinical Center, 10 Center Drive, Bldg. 10, Room 1C240, Bethesda, MD, 20892, USA. suraj.rajasimhan@nih.gov.
² Office of the Clinical Director, Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Intramural
Comment

MeSH terms

Aged
Humans
Janus Kinase Inhibitors*
Thromboembolism* / chemically induced
Thromboembolism* / epidemiology

Substances

Janus Kinase Inhibitors